February 15, 2023 – For the seventh consecutive year, McKesson has received approval from CMS to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed℠ electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
As a CMS-approved QCDR, Practice Insights℠, a performance analytics tool powered by Ontada®, can collect and report clinical data on behalf of clinicians for standard MIPS with the additional ability to report on custom QCDR quality measures to drive improvements in quality and cost of care.
Six custom QCDR measures identified by physician leaders in The US Oncology Network (The Network) and submitted by McKesson were approved by CMS. Additionally, CMS approved two custom measures developed by the American Society of Clinical Oncology (ASCO) that will also be supported by McKesson’s QCDR. Combined, they include:
- Advance Care Planning in Metastatic Cancer Patients
- Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
- Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy
- Patient-Reported Pain Improvement
- Supportive Care Drug Utilization in Last 14 Days of Life
- Utilization of GCSF in Metastatic Colorectal Cancer (Also included in the Advancing Cancer Care MVP)
- Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center – Avoidance of Overuse (Developed by ASCO)
- Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center (Developed by ASCO)